Document is current
Any future updates will be listed below
-
Authors
Kosti, Paris
Abram-Saliba, Johan
Pericou-Troquier, Laetitia
Pavelot, Sarah
Ruggeri, Tiphaine
Laffaille, Marc
Irving, Melita https://orcid.org/0000-0002-6849-7194
Coukos, George
Lanitis, Evripidis https://orcid.org/0000-0002-8194-5414
Dunn, Steven M. https://orcid.org/0000-0002-7402-9581
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct06756035 at ClinicalTrials.govnct06255665 at ClinicalTrials.govDocuments that mention this clinical trial
586 Trial in progress: a phase 1, first-in-human study of CT-95, a mesothelin (MSLN)-directed bispecific cell engager (TCE) in subjects with advanced solid tumors
https://doi.org/10.1136/jitc-2025-sitc2025.0586
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager
https://doi.org/10.1136/jitc-2024-010063
nct03872206 at ClinicalTrials.govDocuments that mention this clinical trial
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager
https://doi.org/10.1136/jitc-2024-010063
Documents that mention this clinical trial
Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager
https://doi.org/10.1136/jitc-2024-010063
-
Funding
Funding for this research was provided by:
Swiss National Science Foundation (SNSF 310030)
Ludwig Cancer Research (Not applicable (no award number))
Fondazione Teofilo Rossi di Montelera e di Premuda (Not applicable (no award number))
- License Information
